Barclays analyst Andrew Mok lowered the firm’s price target on Humana (HUM) to $234 from $245 and keeps an Equal Weight rating on the shares. If company “executes flawlessly,” $14 of earnings per share next year is possible, the analyst tells investors in a research note. However, the firm says Humana’s “execution risk is real.” It models break-even individual Medicare Advantage margins and $11 in EPS.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUM:
- White House postpones healthcare proposal after backlash, MS Now says
- White House expected to unveil extension of Obamacare subsidies, Politico says
- Trump Weekly: U.S. ends reciprocal food tariffs, levy on Brazil’s coffee
- Plus Therapeutics’ assay secures national coverage agreement with Humana
- Midday Fly By: Microsoft, Nvidia invest in Anthropic